GMP – Page 52 – Pharma.Tips

Inefficient CIP cycle during equipment changeover – validated efficiency improvement

Improving Equipment Changeover Efficiency in CIP Cycles Manufacturing facilities often encounter issues with inefficient Clean-In-Place (CIP) cycles, particularly during equipment changeover. This inefficiency can lead to extended downtime, increased labor…

Documentation not aligned to WHO during remediation planning – gap remediation roadmap

Developing a Roadmap for Remediation Planning Aligned with WHO Standards In an environment where global standards dictate compliance, pharmaceutical manufacturers often face challenges in ensuring their documentation aligns with WHO…

Inadequate WHO GMP training during prequalification preparation – avoiding repeat WHO observations

How to Address Inadequate WHO GMP Training During Prequalification Preparation to Prevent Repeat Observations In the pharmaceutical industry, inadequate training related to WHO Good Manufacturing Practice (GMP) can result in…

Documentation not aligned to WHO during WHO inspection – CAPA aligned to WHO standards

Ensuring Documentation Alignment with WHO During Inspections: A CAPA Playbook In the landscape of pharmaceutical manufacturing, maintaining compliance with the World Health Organization (WHO) standards during inspections is crucial. Discrepancies…

Inefficient CIP cycle during multi-product campaigns – inspection-ready cleaning optimization

Optimizing Cleaning Processes for Improved Efficiency in Multi-Product Campaigns In the highly regulated pharmaceutical manufacturing landscape, inefficiencies in cleaning processes can lead to significant operational setbacks. One critical flashpoint is…

Documentation not aligned to WHO during remediation planning – WHO inspector expectations explained

Mitigating Documentation Misalignment with WHO Expectations during Remediation Planning In the dynamic environment of pharmaceutical manufacturing and quality control, operational challenges can lead to documentation discrepancies, particularly during remediation planning.…

WHO GMP gap identified during remediation planning – avoiding repeat WHO observations

Addressing WHO GMP Gaps During Remediation Planning to Prevent Recurrence In today’s regulatory landscape, pharmaceutical manufacturers face increasing scrutiny from global health authorities. Observations from the World Health Organization (WHO)…

Supplier WHO GMP non-compliance during WHO inspection – CAPA aligned to WHO standards

Addressing Supplier Non-Compliance with WHO GMP During Inspections: A Playbook for Pharma Professionals Supplier non-compliance with WHO GMP standards poses a significant risk to pharmaceutical operations, leading to financial losses…

Extended cleaning duration during CPV review – cycle time reduction with compliance assurance

Addressing Extended Cleaning Duration during CPV Review for Cycle Time Reduction and Compliance Extended cleaning durations discovered during a Continued Process Verification (CPV) review can jeopardize both compliance and manufacturing…

Inconsistent alignment with WHO TRS during API sourcing – WHO inspector expectations explained

Addressing Inconsistencies with WHO TRS in API Sourcing: A Practical Playbook The pharmaceutical industry faces increasing scrutiny regarding the alignment with World Health Organization (WHO) Technical Reports Series (TRS) during…

Inconsistent alignment with WHO TRS during remediation planning – gap remediation roadmap

Addressing Gaps in WHO TRS Compliance During Remediation Planning Pharmaceutical professionals often face significant challenges when aligning their processes with the World Health Organization’s Technical Report Series (WHO TRS), particularly…

Inconsistent alignment with WHO TRS during prequalification preparation – evidence pack for WHO audits

Addressing Inconsistent Alignment with WHO TRS During Prequalification Preparation In the pharmaceutical industry, aligning with the WHO TRS (Technical Report Series) is crucial for securing prequalification (PQ) status. Yet, inconsistencies…